10times
27 Apr 2021Ended

Children Are Not Small Adults Importance of Biopharmaceutics and Dose Design in Pediatric Drug Development

AboutSpeakersExhibitorsReviewsPhotos

Estimated Turnout

upto 100
Delegates
Based on previous editions

Editions

Apr 2021

Frequency

Not Available
Claim event to edit details

However, developing drug products for pediatric populations is a challenging undertaking due to the physiological differences between children and .. Read more adults. Join this webcast to hear a distinguished speaker discuss the current challenges in pediatric drug development programs including predicting oral absorption, and in vitro and in silico methods that can be applied to predict behavior in pediatric populations. During this session, a Catalent expert will highlight formulation and dosage form development strategies based on target product profiles that can help bring patient centric treatments to market faster. Andrew’s technical background is in colloid and surface science. After completing his undergraduate studies in Chemistry at the University of Bristol in 1996, Andrew performed research for his doctorate at the Bristol Colloid Centre (BCC) in biocompatible coatings. Andrew has spent the last 20 years in the CDMO industry, in a variety roles and has supported and managed a number of paediatric drug product development projects. Andrew is now a Director of Open Innovation at Catalent with a strong interest in the evolution of paediatric formulation and testing approaches.

  • Share your Experience
  • Organizer
Logo Follow Company

Business Review Webinars

UK198 Total Events / 46 Upcoming Events

More Events From The Organizer